RxDoctor Payments Data

Jeffrey Smith, MD

Dermatology · Watertown, SDNPI 1245550425

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,137 of the $1,378 with a category attached, or 82.5%. 9 manufacturers reported payments, led by AbbVie at 42.0% of the total. Reporting peaked in 2024 at $377 and has fallen 61.4% since, to $145 in 2025.

$1,378in general payments, 2019–2025

Across 92 payments — averaging $14.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$579
  • Regeneron Healthcare Solutions, Inc.$395
  • Lilly USA, LLC$207
  • Amgen$104
  • Novartis$31
  • Axsome Therapeutics, Inc.$23
  • plus $39 from 3 others

What the payments were for

  • Food & beverage$1,13783%
  • Education$24117%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,378 in reported general payments places this provider in the 55th percentile of 44 dermatology providers in South Dakota.

See all dermatology providers in South Dakota

Medicare billing

Part B allowed, 2024
$235,037
Medicare patients
1,016
Services billed
4,603

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast12$66,582
Dupixent PenDupilumab15$55,151
Clobetasol Propionate156$9,690
Acitretin12$3,244
Fluocinonide62$2,717
Metronidazole44$2,578
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc112$2,356
Fluorouracil21$1,635
Triamcinolone Acetonide182$1,597
Clindamycin Phosphate22$1,061
Clotrimazole25$978
Ketoconazole65$939
ValacyclovirValacyclovir Hcl33$887
Minocycline Hcl15$878
Hydrocortisone204$868

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$104$66,58212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 44 dermatology providers in South Dakota.

Other dermatology in Watertown

See the full list for South Dakota

Where these figures come from

Is this you, or does something look wrong? →